| Identification | Back Directory | [Name]
N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide | [CAS]
1776112-90-3 | [Synonyms]
CPI-637
PF 6747775
PF-06747775
MAVELERTINIB
Mavelertinib( PF-06747775)
N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methylpyrazol-4-yl)amino]-9-methylpurin-2-yl]pyrrolidin-3-yl]prop-2-enamide
N-((3R,4R)-4-fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidin-3-yl)acrylamide
2-Propenamide, N-[(3R,4R)-4-fluoro-1-[6-[(3-methoxy-1-methyl-1H-pyrazol-4-yl)amino]-9-methyl-9H-purin-2-yl]-3-pyrrolidinyl]- | [Molecular Formula]
C18H22FN9O2 | [MDL Number]
MFCD29079007 | [MOL File]
1776112-90-3.mol | [Molecular Weight]
415.42 |
| Hazard Information | Back Directory | [Uses]
PF 06747775 is an orally available inhibitor of the epidermall growth factor receptor (EGFR) mutant form T790M showing antineoplastic activity. |
|
|